The objective of this study was to provide a comprehensive overview of the CAR-T (chimeric antigen receptor T-cells) therapy landscape in Russia, including the types of products used, their target antigens, indications, the role of CAR-T therapy in treatment pathways, clinical trials, marketing authorization, and production infrastructure data. A key feature of the Russian landscape is the emergence of a hybrid ecosystem in which academically developed products coexist with the first industrial CAR-T products. Monospecific constructs targeting cluster of differentiation (CD) 19 are the most common. Bispecific and polyspecific CAR-T variants are also being developed. This technology has been used for the treatment of nine lymphoproliferative diseases. In the vast majority of cases, CAR-T therapy was used as a salvage therapy in later stages of treatment. The expected number of patients in clinical trials exceeds 200. One commercial CAR-T product has been approved, and another is in the final stages of research and obtaining marketing authorization. The number of licensed organizations with CAR-T production infrastructure is growing. Currently, five organizations hold authorizations for the production and use of individual biomedical cell products, and five hold licenses for the manufacture of gene therapy biological medicinal products. Further development of this technology will depend on how successfully key challenges are addressed, including production scale-up, patient routing, payment models, and the systematic collection of real-world clinical data. For BRICS countries, the Russian experience may be considered one example of how complex and high-cost cell therapy can be introduced into a national healthcare system. International cooperation on regulatory and funding issues, as well as joint clinical trials of industrial CAR-T technologies, could accelerate the development of this field in the BRICS countries.